Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care.
'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.'
Key Findings from the Report:
Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029.
Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments.
True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment.
Why It Matters Now
The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes.
'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.'
Audience Impact
This research is essential for:
Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery.
With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier.
Get the Report
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: https://kaloramainformation.com/product/molecular-point-of-care-mpoc-2024-2029/
For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama Informationsheri.davie@scienceandmedicinegroup.com
About Kalorama Information
Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors.
Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD.
Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends.
With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis.
Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets.
For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Rakyat Post
20 hours ago
- Rakyat Post
Malaysia Records First COVID-19 Death In 2025
Subscribe to our FREE Malaysia has recorded its first COVID-19-related death of 2025, according to a statement released by the Ministry of Health (MoH) on 19 June. The fatality occurred during Epidemiological Week 24 (8–15 June). The individual, who had serious pre-existing health conditions such as heart disease and diabetes, had not received the second booster dose of the COVID-19 vaccine. MoH noted that this was the first COVID-19 death since 26 May 2024, and a significant drop compared to the 57 COVID-related deaths reported in 2024. COVID-19 Cases on the Rise, But Situation Under Control As of Week 24, Malaysia has reported 21,738 cumulative COVID-19 cases in 2025, with the weekly average hovering around 900 cases. However, MoH did flag a 68% week-on-week spike, with 3,379 cases reported in Week 24 compared to 2,011 the previous week. Despite the increase, the ministry assured that the national COVID-19 situation remains stable and below the national alert threshold. In terms of severe cases, six patients were admitted to the ICU, all with underlying health issues. All have since been discharged from intensive care; four have returned home, while two remain in regular hospital wards for follow-up treatment. New Variant on the Radar: NB.1.8.1 or 'Nimbus' The World Health Organisation (WHO) is closely monitoring the spread of NB.1.8.1, a Photo: Freepik WHO has classified Nimbus as a Variant Under Monitoring (VUM) due to its rapid transmission and potential health risks. Nimbus spreads faster than previous variants. Common symptoms include: razor-blade-like sore throat, fatigue, mild cough, fever, muscle aches and nasal congestion. What You Can Do Health experts continue to urge the public to take precautions, especially as new variants emerge. Wear a high-quality mask in crowded indoor spaces, improve indoor ventilation: open windows, use fans or air purifiers, get tested if you're feeling unwell or exposed to COVID-19, and stay home when sick to reduce the risk of transmission. Photo: Malay Mail While Malaysia's current COVID-19 situation remains under control, this latest death and the emergence of new variants serve as reminders that vigilance and public health measures remain crucial. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.
Malaysian Reserve
a day ago
- Malaysian Reserve
Infectious Disease Testing Market Remains Dynamic Amid Post-Pandemic Shifts and New Innovations
ARLINGTON, Va., June 19, 2025 /PRNewswire/ — Kalorama Information, a trusted source for healthcare market intelligence, released insights into the evolving global market for infectious disease testing through the In Vitro Diagnostics Business Outlook newsletter. Despite the decline in COVID-19 testing, the overall infectious disease diagnostics market remains robust, supported by sustained demand for non-COVID tests and the adoption of next-generation technologies across both laboratory and point-of-care (POC) settings. With testing essential for diagnosing, monitoring, and containing a wide range of infections—from respiratory illnesses and bloodborne viruses to sepsis and gastrointestinal pathogens—the market continues to attract significant attention and investment. Kalorama's latest report highlights a steady shift in growth drivers, with POC solutions, molecular platforms, and advanced immunoassays gaining ground. 'Infectious disease diagnostics continues to be one of the most innovative segments of the IVD industry,' said Daniel Granderson, Senior Editor of Kalorama Information. 'New technologies are not only enhancing diagnostic speed and accuracy but are also reshaping where and how testing is performed—bringing more solutions to decentralized and resource-limited settings.' Highlights from the article include: Strong global demand for lab-based immunoassays and molecular tests Continued innovation in syndromic panels, microfluidics, and cartridge-based POC platforms A growing share of the market shifting toward emerging regions, with Asia Pacific and other developing areas seeing increased diagnostic infrastructure and demand Major industry players—including Roche, Abbott, Danaher, and QIAGEN—introducing new products to address unmet needs in STIs, sepsis, and respiratory diseases The report also profiles emerging innovators bringing AI-powered diagnostics, rapid sepsis panels, and cost-effective molecular tools to market, emphasizing the industry's ongoing focus on speed, accuracy, and accessibility. For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook. About IVD Business Outlook In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Website:
